Screening, Radiolabeling and Biodistribution of Lung Tumor-targeting Peptide YC11 by in vivo Phage Display

doi:10.7503/cjcu20120995

Abstract

Abstract:

In vivo phage display was used to isolate tumor-targeting peptides. A cycloheptapeptide CSIHYPLSC(YC11) ligand targeting A549 human lung tumor was identified and radioiodinated. The labeled complex ¹³¹I-YC11 and ¹³¹I-NGR(control peptide) were isolated and purified by reverse phase high-performance liquid chromatography(RP-HPLC). The radiochemical purity was estimated to be better than 99%. The biodistribution results of ¹³¹I-YC11 and control peptide ¹³¹I-NGR in mice bearing A549 tumor demonstrated that the tumor-to-blood, tumor-to-heart, tumor-to-lung and tumor-to-liver uptake ratios of ¹³¹I-YC11 were 0.62, 2.06, 1.11 and 0.81, respectively, and slightly higher than those of ¹³¹I-NGR. The uptake of ¹³¹I-YC11 in tumor was 2.79%ID/g, more than that of ¹³¹I-NGR(1.61%ID/g). ¹³¹I-YC11 was more concentrated in A549 tumor than ¹³¹I-NGR. Conclusively, YC11 could be a potential lung cancer targeting agent.

Key words: Phage display, Targeting peptide, Lung tumor, Biodistribution, Radiolabeling

CLC Number:

TrendMD:

LIANG Kun, CHU Tai-Wei. Screening, Radiolabeling and Biodistribution of Lung Tumor-targeting Peptide YC11 by in vivo Phage Display[J]. Chem. J. Chinese Universities, 2013, 34(4): 870.

References

[1] Xie J., Zhu J. H., Chem. J. Chinese Universities, 2011, 32(7), 1532—1536(谢江, 朱建华. 高等学校化学学报, 2011, 32(7), 1532—1536)

[2] Lü F., Li Y. Z., Wu L., Liu T. J., Chem. J. Chinese Universities, 2011, 32(5), 1010—1012(吕丰, 李艳周, 武莉, 刘天军. 高等学校化学学报, 2011, 32(5), 1010—1012)

[3] Sun L. Y., Chu T. W., Wang Y., Wang X. Y., Chem. J. Chinese Universities, 2007, 28(4), 621—626(孙丽艳, 褚泰伟, 王毅, 王祥云. 高等学校化学学报, 2007, 28(4), 621—626)

[4] He X. F., Na M. H., Kim J. S., Lee G. Y., Park J. Y., Hoffman A. S., Nam J. O., Han S. E., Sim G. Y., Oh Y. K., Kim I. S., Lee B. H., Mol. Pharm., 2011, 8(2), 430—438

[5] Zang L. Q., Shi L., Guo J., Pan Q., Wu W., Pan X. D., Wang J. Y., Cancer Lett., 2009, 281(1), 64—70

[6] Tu X. G., Zang L. Q., Lan D. Y., Liang W. C., Mol. Med. Rep., 2009, 2(6), 1005—1010

[7] Oyama T., Sykes K. F., Samli K. N., Minna J. D., Johnston S. A., Brown K. C., Cancer Lett., 2003, 202(2), 219—230

[8] Lee T. Y., Lin C. T., Kuo S. Y., Chang D. K., Wu H. C., Cancer Res., 2007, 67(22), 10958—10965

[9] Pasqualini R., Koivunen E., Ruoslahti E., Nat. Biotechnol., 1997, 15(6), 542—546

[10] Arap W., Pasqualini R., Ruoslahti E., Science, 1998, 279(5349), 377—380

[11] Corti A., Curnis F., Arap W., Pasqualini R., Blood, 2008, 112(7), 2628—2635

[12] Farah K., Farouk N., J. Labelled Compd. Radiopharm., 1998, 41(4), 255—259

[13] Seevers R. H., Counsell R. E., Chem. Rev., 1982, 82(6), 575—590

[14] Chu T. W., Li R. J., Hu S. W., Liu X. Q., Wang X. Y., Nucl. Med. Biol., 2004, 31(2), 199—203

[15] Su Z. F., Ballinger J. R., Rauth A. M., Abrams D. N., Billinghurst M. W., Bioconjugate Chem., 2000, 11(5), 652—663

[16] Zhang X. G., Su Z. F., Ballinger J. R., Rauth A. M., Pollak A., Thornback J. R., Bioconjugate Chem., 2000, 11(3), 401—407

[17] Brown J. M., Workman P., Radiat. Res., 1980, 82(1), 171—190

[18] White R. A. S., Workman P., Brown J. M., Radiat. Res., 1980, 84(3), 542—561

[19] Chapman J. D., Engelhardt E. L., Stobbe C. C., Schneider R. F., Gerald G. E., Radiother. Oncol., 1998, 46(3), 229—237

[20] Josefsson M., Grunditz T., Ohlsson T., Ekblad A., Acta Physiol. Scand., 2002, 175(2), 129—137